CoronaryAtlas logo
CoronaryAtlas
Valine
Pathway / Myocardial injury (shared endpoint)

Valine

metabolite

Ischemic stress alters branched-chain amino acid metabolism and protein turnover in cardiomyocytes.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencelow
RationaleBranched-chain amino acid elevation is an early metabolic response to myocardial ischemia.
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresNon-Type-I-associated
R — rupture / Type-I
—
C — non-Type-I
56
A — assay feasibility
42
E — evidence strength
35
T1DI (composite)
4
Specificity differential (R−C)-40.6
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmian/a
2hypoxemia / respiratory failuren/a
2hypertensive emergencyn/a
2high-demand / peri-operative stressn/a
3sudden cardiac deathmag 2
4aPCI-related periproceduralmag 1
4bstent thrombosisn/a
4cin-stent restenosisn/a
5CABG-relatedmag 2
Coverage: 3/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 4 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research

Literature evidence(1)